Abstract
Background
We sought to examine the temporal variations in the rate of both bare‐metal stent (BMS) and drug‐eluting stent (DES) use for off‐label indications after the reports of an increased risk of very late stent thrombosis in patients with DES at the 2006 meeting of the European Society of Cardiology (ESC).
Hypothesis
To determine whether the decrease in use of DES has affected both on and off‐label indications.
Methods
The study cohort included patients undergoing coronary intervention in a large regional registry, the Blue Cross Blue Shield of Michigan Cardiovascular Consortium (BMC2). Patient demographic and clinical characteristics for patients with DES in the third quarter of 2006 (pre‐ESC) were compared to those from the fourth quarter of 2008 (post‐guideline changes). Use of DES for off‐label indications, such as ST‐segment elevation myocardial infarction (STEMI), in‐stent restenosis (ISR), and saphenous vein graft (SVG) interventions, were evaluated.
Results
The overall deployment of DES fell sharply from 83% pre‐ESC to a plateau of 58% in the first quarter of 2008. This corresponded to a rise in BMS use, while angioplasty procedures stayed the same. The STEMI subgroup showed the most dramatic change, from 78% to only 36%. Off‐label use in SVGs showed a similar trend, from 74% to 43%. Drug‐eluting stent deployment for ISR was less affected, though it also fell 25% (from 79%–56%).
Conclusions
The use of DES has fallen dramatically from June 2006 to December 2008, particularly for nonapproved indications. Our study provides a real‐world assessment of contemporary change in DES use in response to the presentation of negative observational studies. Copyright © 2010 Wiley Periodicals, Inc.
Full Text
The Full Text of this article is available as a PDF (490.4 KB).
References
- 1. Abbott JD, Voss MR, Nakamura M, et al. Unrestricted use of drug‐eluting stents compared with bare‐metal stents in routine clinical practice. J Am Coll Cardiol 2007; 50: 2029–2036. [DOI] [PubMed] [Google Scholar]
- 2. Nordmann AJ, Briel M, Bucher HC. Mortality in randomized controlled trials comparing drug‐eluting vs bare‐metal stents in coronary artery disease: a meta‐analysis. Eur Heart J 2006; 24: 2737–2739. [DOI] [PubMed] [Google Scholar]
- 3. Pfisterer M, Brunner‐La Rocca HP, Buser PT, et al. Late clinical events after clopidogrel discontinuation may limit benefit of drug‐eluting stents: an observational study of drug‐eluting vs bare metal stents. J Am Coll Cardiol 2006; 48: 2584–2591. [DOI] [PubMed] [Google Scholar]
- 4. Lagerqvist B, James SK, Stenestrand U, et al. Long‐term outcomes with drug‐eluting stents vs bare metal stents in Sweden. N Eng J Med 2007; 356: 1009–1019. [DOI] [PubMed] [Google Scholar]
- 5. Farb A, Boam AB. Stent thrombosis redux—the FDA perspective. N Engl J Med 2007; 356: 984–987. [DOI] [PubMed] [Google Scholar]
- 6. Kline‐Rogers E, Share D, Bondie D, et al. Development of a multicenter interventional cardiology database: the Blue Cross Blue Shield of Michigan Cardiovascular Consortium (BMC2) experience. J Interv Cardiol 2002; 15: 387–392. [DOI] [PubMed] [Google Scholar]
- 7. Moscucci M, Kline‐Rogers E, Share D, et al. Simple bedside additive tool for prediction of in‐hospital mortality after percutaneous coronary interventions. Circulation 2001; 104: 263–268. [DOI] [PubMed] [Google Scholar]
- 8. Moscucci M, Eagle KA, Share D, et al. Public reporting and case selection for percutaneous coronary interventions: an analysis from two large multicenter percutaneous coronary intervention databases. J Am Coll Card 2005; 45: 1759–1765. [DOI] [PubMed] [Google Scholar]
- 9. Moscucci M, Rogers EK, Montoye C, et al. Association of a continuous quality improvement initiative with practice and outcome variations of a contemporary percutaneous coronary interventions. Circulation 2006; 113: 814–822. [DOI] [PubMed] [Google Scholar]
- 10. Grines CL, Bonow RO, Casey DE Jr, et al. Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents. J Am Coll Cardiol 2007; 49: 734–739. [DOI] [PubMed] [Google Scholar]
- 11. Tu JV, Bowen J, Chiu M, et al. Effectiveness and safety of drug‐eluting stents in Ontario. N Engl J Med 2007; 357: 1393–1402. [DOI] [PubMed] [Google Scholar]
- 12. James SK, Stenestrandn U, Lindback J, et al. Long‐term safety and efficacy of drug‐eluting stents in Sweden. N Eng J Med 2009; 360: 1933–1945. [DOI] [PubMed] [Google Scholar]
- 13. Stone GW, Lansky AJ, Pocock SJ, et al. Paclitaxel‐eluting stents vs bare‐metal stents in acute myocardial infarction. N Eng J Med 2009; 360: 1946–1959. [DOI] [PubMed] [Google Scholar]
- 14. Kastrati A, Mehilli J, von Beckerath N, et al. Sirolimus‐eluting stent or paclitaxel‐eluting stent vs balloon angioplasty for prevention of recurrences in patients with coronary in‐stent restenosis. JAMA 2005; 293: 165–171. [DOI] [PubMed] [Google Scholar]
- 15. Dibra A, Kastrati A, Wehilli J, et al. Paclitaxel‐eluting or sirolimus‐eluting stents to prevent restenosis in diabetic patients. N Engl J Med 2005; 353: 663–670. [DOI] [PubMed] [Google Scholar]
- 16. Boyden TF, Nallamothu BK, Moscucci M, et al. Meta‐analysis of randomized trials of drug‐eluting stents vs bare metal stents in patients with diabetes mellitus. Am J Cardiol 2007; 99(10): 1399–1402. [DOI] [PubMed] [Google Scholar]
- 17. Khanderia U, Townsend KA, Eagle K, et al. Statin initiation following coronary artery bypass grafting. Chest 2005; 127: 455–463. [DOI] [PubMed] [Google Scholar]
- 18. Roe MT, Chen AY, Cannon CP, et al. Temproal changes in the use of drug‐eluting stents for patients with non‐ST‐segment‐elevation myocardial infarction undergoing percutaneous coronary intervention. Circ Cardiovasc Qual Outcomes 2009. [DOI] [PubMed] [Google Scholar]